title: Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis.
abstract: In the light of the relationship between the MDR1 G2677T polymorphism and the risk of leukemia remains inclusive or controversial. For better understanding of the effect of MDR1 G2677T polymorphism on leukemia risk, we performed a meta-analysis. Eligible studies were identified through a search of electronic databases such as PubMed, Excerpta Medica Database (Embase), Cochrane Library, and Chinese Biomedical Literature Database (CBM). The association between the MDR1 G2677T polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CI). A total of seven publications including eight studies with 1,229 cases and 1,097 controls were included in the meta-analysis. There was no association between MDR1 G2677T polymorphism and leukemia risk in all of five models in overall populations (T vs. G: OR = 1.00, 95% CI = 0.88-1.12, P = 0.914; TT vs. GG: OR = 0.97, 95% CI = 0.75-1.26, P = 0.812; TG vs. GG: OR = 1.00, 95% CI = 0.92-1.08, P = 0.939; TT vs.
  OR = 0.98, 95% CI = 0.67-1.43, P = 0.906; TT/TG vs. GG: OR = 1.00, 95% CI = 0.95-1.06, P = 0.994). However, the significant association was found in others (Table 2) under the homozygote model (TT vs. GG: OR = 0.68, 95% CI = 0.48-0.94, P = 0.020) and recessive model (TT vs.
  OR = 0.63, 95% CI = 0.43-0.92, P = 0.016). In the subgroup analysis, according to the type of leukemia, significant association was found between MDR1 G2677T polymorphism and myeloid leukemia but not lymphoblastic leukemia (TT vs. GG: OR = 0.66, 95% CI = 0.46-0.95, P = 0.026; TT vs.
  OR = 0.56, 95% CI = 0.38-0.84, P = 0.005). The results suggested that there was no association between MDR1 G2677T polymorphism and leukemia risk in overall populations, but significant association was found in others populations (Asians and Africans), and myeloid leukemia indicated that G2677T polymorphism might be a protective factor in the susceptibility of myeloid leukemia and in Asians and Africans.
authors.affiliation: Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, People's Republic of China, xueying201120521@163.com.
authors.forename: Yulan
authors.initials: Y
authors.lastname: Yan
authors.forename: Hongjie
authors.initials: H
authors.lastname: Liang
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.forename: Yu
authors.initials: Y
authors.lastname: He
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.forename: Ruolin
authors.initials: R
authors.lastname: Li
authors.forename: Shan
authors.initials: S
authors.lastname: Li
authors.forename: Xue
authors.initials: X
authors.lastname: Qin
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1